Tata India Pharma & Healthcare Fund Direct IDCW NAV today
AMFI: 135807ISIN: INF277K010B0MUTF_IN: TATA_INDI_PHAR_3FDOKOTata Mutual FundSectoral / Thematic funds
NAV ₹34.5871
NAV for 23 Oct 2026. Declared once a day.
- Fund sizeAssets under management. The money the fund manages for all its investors, across every plan, at the end of the month.
- ₹1,511 CrSep 2026
- Expense ratioTotal expense ratio. What the fund charges each year as a share of the money invested, taken out of the NAV every day, so the returns shown are already after it.
- 1.10%14 Oct 2026
- Exit loadExit load. A charge, as a share of the amount redeemed, on units sold before a set period has passed since they were bought.
- 0.25%if sold within 30 days
- P/EP/E. What the fund pays for each rupee of yearly profit its companies earn: the total value of its shares divided by those companies' last four quarters of profit, each in proportion to what the fund holds. The profit leaves out one-off items (exceptional items and businesses sold or demerged), so one company's one-off gain cannot make the fund look cheap. A loss-making company lowers the profit. Shown when at least 80% of the fund's shares are counted.
- 38.730 Sep 2026
- Risk levelRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month.
- Very HighAug 2026
- HoldingsHoldings. The number of different securities in the fund's latest monthly portfolio: shares, bonds, money market paper and units of other funds, not cash, overnight lending or futures.
- 4230 Sep 2026
- LaunchedLaunch date. The day the fund first allotted units to investors, at the close of its new fund offer.
- 28 Dec 2015
Tata India Pharma & Healthcare Fund returns
Read from the direct plan's growth option: an IDCW plan's NAV falls by every payout, so it carries no return of its own
Over each window to 23 Oct 2026
| Over | ReturnTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). | BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back. | Rank in categoryRank in category. The fund's place among the funds of its category with a return over the same window, highest return first. | Category medianCategory median. The middle return of the funds in the category over the same window: half returned more, half less. | Middle halfMiddle half of the category. The returns of the fund a quarter of the way down the category and the fund a quarter of the way up, over the same window: half the category's funds returned between the two. |
|---|---|---|---|---|---|
| 1 week | −3.36% | – | – | – | – |
| 1 month | −9.91% | – | 206 of 254 | −8.23% | −9.5% to −6.6% |
| 3 months | −8.29% | – | 205 of 250 | −6.23% | −7.7% to −4.3% |
| 6 months | +1.96% | – | 66 of 250 | −3.43% | −6.3% to +2.1% |
| 1 year | −1.58% | +16.77%to 30 Sep 2026 | 79 of 228 | −5.19% | −9.3% to +0.6% |
| 3 years | +16.81% | +21.25%to 30 Sep 2026 | 36 of 141 | +12.40% | +8.6% to +16.8% |
| 5 years | +13.51% | +14.60%to 30 Sep 2026 | 32 of 106 | +10.89% | +8.1% to +14.6% |
| 10 years | +13.94% | +12.65%to 30 Sep 2026 | 32 of 70 | +13.74% | +11.5% to +15.5% |
₹10,000 put in on 29 Dec 2015 is ₹35,624 at the NAV of 23 Oct 2026Growth of ₹10,000. What ₹10,000 put in at the NAV of the first day would be worth at the latest NAV, after the fund's expenses and before tax and any exit load.Over a year and longer, a return is the yearly rate. Benchmark: BSE Healthcare TRI, over the same days as the fund, or to the month end its cell names. Rank, median and middle half among the Direct plans of Sectoral / Thematic funds, each fund's return to its latest NAV on or before 25 Oct 2026.
At the month end, 30 Sep 2026
| Over | FundTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). | BenchmarkBenchmark return. The change in the benchmark index's total return level over the same dates as the fund's return, as a yearly rate over a year and longer. |
|---|---|---|
| 1 year | +9.46% | +16.77% |
| 3 years | +18.48% | +21.25% |
| 5 years | +14.32% | +14.60% |
| 10 years | +14.77% | +12.65% |
| Since launch | +13.29% | +11.28% |
Benchmark: BSE Healthcare TRI. Both as the fund house states them for the month.
Return in each calendar year
- Fund, Direct GrowthCalendar year return. The change in NAV from the last NAV of one year to the last NAV of the next.
- Loss
Highest year to Dec 2020, +66.9%; lowest year to Dec 2016, −13.1%
Tata India Pharma & Healthcare Fund SIP returns
₹10,000 on the 1st of every month, valued at the NAV of 23 Oct 2026
| Period | InvestedAmount invested. ₹10,000 on the 1st of every month, or the next day the fund priced, added up over the period. | Value todayValue today. What the units bought by every instalment are worth at the latest NAV. | Invested against value today | SIP returnSIP return (XIRR). The yearly rate that, applied to each monthly instalment from the day it was invested, gives the value of all the units today. | After stamp dutySIP return after stamp duty. The same SIP return with stamp duty of 0.005% taken from every instalment since 1 Jul 2020, so ₹10,000 buys ₹9,999.50 of units. | Stamp dutyStamp duty paid. The stamp duty on all the instalments, in rupees: 0.005% of each purchase made since 1 Jul 2020. |
|---|---|---|---|---|---|---|
| 1 year12 instalments | ₹1,20,000 | ₹1,18,022₹1,18,016 after stamp duty | −3.17% | −3.18% | ₹6 | |
| 3 years36 instalments | ₹3,60,000 | ₹3,92,697₹3,92,677 after stamp duty | +5.81% | +5.81% | ₹18 | |
| 5 years60 instalments | ₹6,00,000 | ₹8,44,253₹8,44,211 after stamp duty | +13.74% | +13.74% | ₹30 | |
| 10 years120 instalments | ₹12,00,000 | ₹28,83,100₹28,83,040 after stamp duty | +16.77% | +16.77% | ₹38 | |
| Since Dec 2015130 instalments | ₹13,00,000 | ₹32,51,161₹32,51,101 after stamp duty | +16.07% | +16.07% | ₹38 |
From the Direct Growth plan's NAV, since an IDCW plan's NAV falls by each payout.
Rolling returns
Per cent a year, every window from 29 Dec 2015 to 23 Oct 2026
Lowest to highestAverage
LowestLowest rolling return. The worst yearly return of any window of this length in the fund's history, one window starting on each day it priced.AverageAverage rolling return. The average of the yearly returns of every window of this length in the fund's history.HighestHighest rolling return. The best yearly return of any window of this length in the fund's history.Ended higherWindows that ended higher. The share of all the windows of this length in which the NAV ended above where it started.
1 year2,420 windows−17.3%+16.5%+76.3%70.8%
3 years1,927 windows−3.4%+18.2%+30.4%90.9%
5 years1,435 windows+9.3%+18.8%+31.6%100.0%
10 yearsLaunched 28 Dec 2015, needs 11 years of history
Every 5-year window ended higher than it started.From the Direct Growth plan's NAV, since an IDCW plan's NAV falls by each payout.
Tata India Pharma & Healthcare Fund expense ratio and exit load
Per cent of the money invested, a year. Each month shows its last day filed; the parts were redefined from Apr 2026.
- Regular over directDirect and regular plan cost gap. The regular plan's expense ratio less the direct plan's: what buying through a distributor costs each year, since both plans own the same portfolio.
- 1.31 ptsA year, on 14 Oct 2026
- Direct, 30-day averageExpense ratio, 30-day average. The total expense ratio averaged over the last 30 days the fund filed it, which evens out the day-to-day moves in brokerage and levies.
- 1.08%Over the last 29 days filed
- Regular, 30-day averageExpense ratio, 30-day average. The total expense ratio averaged over the last 30 days the fund filed it, which evens out the day-to-day moves in brokerage and levies.
- 2.39%Over the last 29 days filed
Total expense ratio, month by month
- Regular plan
- Direct plan
Direct plan highest 1.20%, Nov 2020.Direct plan lowest 0.61%, Nov 2025.
What the expense ratio is made of
| Part | Direct | Regular |
|---|---|---|
| Base expense ratioBase expense ratio. The part of the expense ratio that pays the fund house and the distributor, before brokerage, transaction costs, levies and GST. | 0.64% | 1.82% |
| Brokerage | 0.11% | 0.11% |
| Transaction costs | 0.01% | 0.01% |
| Statutory levies | 0.34% | 0.48% |
Per cent of assets a year, filed for 22 Oct 2026. The parts add up to that day's total.
Buying and selling
- Exit loadExit load. A charge, as a share of the amount redeemed, on units sold before a set period has passed since they were bought.
- 0.25% of NAV if redeemed /switched out before 30 days from the date of allotment.
- Lump-sum purchases
- Accepted
- Minimum investmentMinimum investment. The smallest amount the plan accepts for a first purchase.
- ₹5,000
- Minimum top-up
- ₹1,000
- Minimum redemption
- ₹500
- SIP
- Accepted
- STP, transfers to another fund
- Not accepted
- SWP, regular withdrawals
- Accepted
- Switches
- Accepted
- Lock-inLock-in. The time after each purchase during which those units cannot be sold.
- None
- SIP minimum
- 100.00/100.00/100.00/100.00/100.00/100.00
- SIP instalments, at least
- 12 Instalments/6 instalments/6 instalments/4 instalments/12 instalments/12 instalments
- SIP dates
- Any day/Any day/Any day/Any day/Monday-Friday/All Business Days
As listed for this plan on 24 Oct 2026.
Tata India Pharma & Healthcare Fund AUM
₹ crore, every plan of the fund together.
- Average assetsAverage assets under management. The money the fund managed, averaged over every day of the quarter, added up across its plans.
- ₹1,534 CrQuarter to Sep 2026
- In the direct plansShare of assets in the direct plans. The direct plans' average assets for the quarter as a percentage of the fund's total; the rest is in the regular plans, bought through distributors.
- 34.7%Of the quarter's average
Average assets by quarter, by plan
- Regular plans
- Direct plans
The latest quarter is the largest since the quarter to Jun 2015.
Assets at each month end
Highest ₹1,565 Cr, Aug 2026.Lowest ₹153 Cr, Mar 2020.
Tata India Pharma & Healthcare Fund portfolio
Portfolio disclosed for 30 Sep 2026.
Holdings on 30 Sep 2026
| Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month. | Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. | Held since. The first month end of the fund's current run of holding this position; marked "or earlier" where that month is the fund's first portfolio on record or the first after a gap in its portfolios. | |||
|---|---|---|---|---|---|
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | Large cap13th | 7.99% | 120.84 | 6,65,178 | Dec 2015or earlier |
| Abbott IndiaPharmaceuticals & Biotechnology | Mid cap183rd | 5.94% | 89.75 | 33,086 | Sep 2025 |
| Healthcare Global EnterprisesHealthcare Services | Small cap593rd | 5.92% | 89.52 | 13,44,012 | Dec 2018 |
| Divi's LaboratoriesPharmaceuticals & Biotechnology | Large cap50th | 5.68% | 85.82 | 92,361 | Sep 2017 |
| Dr. Reddy's LaboratoriesPharmaceuticals & Biotechnology | Mid cap104th | 4.65% | 70.32 | 5,70,312 | Aug 2018 |
| Apollo Hospitals EnterpriseHealthcare Services | Large cap97th | 4.36% | 65.90 | 80,707 | Dec 2016 |
| Rainbow Childrens MedicareHealthcare Services | Small cap481st | 4.30% | 65.07 | 4,95,081 | Jul 2025 |
| CiplaPharmaceuticals & Biotechnology | Large cap99th | 4.22% | 63.78 | 4,73,861 | Apr 2020 |
| Torrent PharmaceuticalsPharmaceuticals & Biotechnology | Large cap61st | 3.76% | 56.88 | 1,18,503 | Aug 2026 |
| Max Healthcare InstituteHealthcare Services | Mid cap111th | 3.71% | 56.09 | 6,03,301 | Jul 2025 |
| LupinPharmaceuticals & Biotechnology | Mid cap105th | 3.14% | 47.40 | 2,33,454 | Nov 2017 |
| Bayer CropscienceFertilizers & Agrochemicals | Small cap343rd | 2.96% | 44.69 | 1,23,182 | Nov 2025 |
| Syngene InternationalHealthcare Services | Small cap359th | 2.85% | 43.10 | 11,79,871 | Mar 2023 |
| Procter & Gamble HealthPharmaceuticals & Biotechnology | Small cap585th | 2.75% | 41.50 | 74,596 | Mar 2026 |
| Sai Life SciencesPharmaceuticals & Biotechnology | Small cap329th | 2.60% | 39.34 | 2,58,078 | Aug 2025 |
Weight is per cent of the fund's net assets; value in ₹ crore.
Cash and receivables on 30 Sep 2026
| Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. | ||
|---|---|---|
| REPO | 0.19% | 2.84 |
| CASH / NET CURRENT ASSET | 0.09% | 1.27 |
| MARGIN MONEY DEPOSITS TOTAL | 0.00% | 0.00 |
Weight is per cent of the fund's net assets; value in ₹ crore.
- Largest holdingLargest holding. The share of the fund in its single largest position, cash and futures not counted as positions.
- 7.99%Sun Pharmaceutical Industries
- Top 5 holdingsTop 5 holdings. The share of the fund held in its five largest positions.
- 30.18%
- Top 10 holdingsTop 10 holdings. The share of the fund held in its ten largest positions.
- 50.53%
- Effective holdingsEffective number of holdings. The number of equal-sized positions that would be as concentrated as the fund's actual weights.
- 26.8Taken over 99.72% of the fund
Asset allocation
Asset allocation. What the fund owns, by kind of asset, each as a share of its net assets; futures and options are shown beside it, not in it, since they are contracts rather than assets bought.- Indian shares99.72%
- Cash and receivables0.28%
Per cent of the fund's net assets.
Large, mid and small cap
Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month.- Large cap26.08%Category 49.50%
- Mid cap33.97%Category 21.62%
- Small cap37.06%Category 26.68%
Per cent of the fund's Indian shares. By the list for the six months to Jun 2026. Shares not on the list: 2.88% of the fund. Category is the average of 249 Sectoral / Thematic funds.
Sector allocation
Sector weight. The fund's shares grouped by the business each company is in, less the futures sold on them, each group as a share of the fund's net assets.3sectors
- Healthcare88.97%Category 12.70%
- Chemicals9.52%Category 1.97%
- Fast Moving Consumer Goods1.23%Category 4.73%
Per cent of the fund's net assets, less the futures sold on its shares, Sep 2026. Category is the average of 254 Sectoral / Thematic funds. Category average. The sector's weight, less the futures sold on it, averaged over the 254 Sectoral / Thematic funds that disclosed a portfolio for Sep 2026. A fund holding none of the sector counts as 0.
Sector allocation month by month
| 13 months | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare35 companies | 88.97% | 92.35% | 92.16% | 92.02% | 93.60% | 93.74% | 94.04% | 94.23% | 95.76% | 94.99% | 90.86% | 96.30% | |
| Chemicals6 companies | 9.52% | 5.55% | 5.82% | 4.17% | 3.95% | 5.19% | 5.03% | 3.33% | 3.34% | 3.69% | 4.14% | 2.17% | |
| Fast Moving Consumer Goods1 company | 1.23% | 1.09% | 1.15% | 1.23% | 1.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Financial Services | 0.00% | 0.50% | 0.00% | 0.00% | 0.40% | 0.67% | 0.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Capital Goods | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Automobile And Auto Components | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Consumer Services | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Information Technology | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Consumer Durables | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Oil Gas & Consumable Fuels | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Telecommunication | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Power | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Per cent of the fund's net assets, less the futures sold on its shares, at each month end, Oct 2025 to Sep 2026; the line runs from Sep 2025.
Bought and sold
Sep 2026 against Aug 2026, position by position.
Positions changed, month by month
- New
- Added
- Trimmed
- Sold out
- New positionsNew positions. Holdings in this month's portfolio that were not in the month before.
- 44.10% of the fund
- Sold outSold out. Holdings in last month's portfolio that are gone from this one, other than a bond or deposit repaid on its due date.
- 33.29% of the fund before
- Added toAdded to. Holdings with more units than the month before. Where the fund states no units, a weight that rose by more than a tenth.
- 14
- TrimmedTrimmed. Holdings with fewer units than the month before. Where the fund states no units, a weight that fell by more than a tenth.
- 8
- UnchangedUnchanged. Holdings with the same number of units as the month before. Their weight can still move with the price.
- 16
- Traded at leastTraded at least. The smaller of the weight bought in new positions and the weight sold out of old ones, cash left out: the least the fund must have bought and sold in the month.
- 3.29%
- Weight that movedWeight that moved. Half the sum of every position's change in weight between the two month ends, new and sold positions included; price moves alone raise it.
- 12.63%
Changes in Sep 2026
| What changed. New: not held the month before. Added or trimmed: more or fewer units than the month before, or, where no units are stated, a weight that moved by more than a tenth. Sold out: held the month before, gone now. Matured: a bond or deposit whose repayment date fell between the two portfolios, so it was repaid rather than sold (one sold in its last days reads the same). | Change in weight. The holding's weight this month less its weight the month before, in percentage points; a price move alone changes it. | ||||
|---|---|---|---|---|---|
| Torrent Pharmaceuticals | Added | 3.76% | 0.12% | +3.64 pts | +1,14,763 |
| Mankind Pharma | Trimmed | 0.77% | 2.91% | −2.14 pts | −1,42,148 |
| GlaxoSmithKline Pharmaceuticals | Trimmed | 0.76% | 2.72% | −1.96 pts | −98,061 |
| Global Health | Sold out | – | 1.68% | −1.68 pts | −1,77,820 |
| PI Industries | Added | 2.59% | 0.95% | +1.64 pts | +1,06,458 |
| Natco Pharma | New | 1.51% | 0.00% | +1.51 pts | +2,75,137 |
| Fortis Healthcare | Trimmed | 1.95% | 3.30% | −1.35 pts | −1,86,357 |
| Navin Fluorine International | New | 1.18% | 0.00% | +1.18 pts | +21,572 |
| Metropolis Healthcare | Sold out | – | 1.11% | −1.11 pts | −2,97,347 |
| Prasol Chemicals | New | 0.88% | 0.00% | +0.88 pts | +1,58,303 |
| Manipal Health Enterprises | Trimmed | 0.59% | 1.24% | −0.65 pts | −1,26,750 |
| Gujarat Fluorochemicals | New | 0.53% | 0.00% | +0.53 pts | +18,164 |
| Abbott India | Added | 5.94% | 5.44% | +0.50 pts | +162 |
| HDFC Life Insurance Company | Sold out | – | 0.50% | −0.50 pts | −1,45,063 |
| Acutaas Chemicals | Added | 1.95% | 1.48% | +0.47 pts | +16,371 |
Weights are per cent of the fund's net assets; a change in weight is in percentage points.
Holdings month by month
| Holding | Oct 25 | Nov 25 | Dec 25 | Jan 26 | Feb 26 | Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries | 9.59%Cut | 7.75%Cut | 7.88%Added | 9.31%Added | 9.66% | 10.34% | 9.87% | 9.38% | 8.51%Cut | 8.59% | 8.43% | 7.99% |
 Abbott India | 4.02%Added | 5.04%Added | 5.48%Added | 5.98%Added | 5.60%Added | 5.89%Added | 5.37% | 5.41% | 4.97%Added | 5.63%Added | 5.44%Added | 5.94%Added |
 Healthcare Global Enterprises | 4.96%Cut | 5.13%Added | 4.84%Added | 5.14%Added | 5.04%Added | 5.39%Added | 5.45% | 5.87%Added | 5.52%Added | 5.85%Added | 6.30% | 5.92% |
 Divi's Laboratories | 3.26%Cut | 3.10% | 5.01%Added | 5.37%Added | 5.94%Added | 5.83% | 5.92% | 5.80% | 5.12%Cut | 6.36%Added | 5.65%Cut | 5.68%Cut |
 Dr. Reddy's Laboratories | 1.63% | 1.70% | 1.75% | 1.78% | 3.04%Added | 3.45%Added | 3.73%Added | 4.02%Added | 4.26%Added | 4.25%Added | 4.21% | 4.65% |
 Apollo Hospitals Enterprise | 5.13% | 4.85% | 4.76% | 4.97% | 5.00%Cut | 4.25%Cut | 4.06% | 4.56%Added | 4.61% | 3.90%Cut | 4.32%Added | 4.36%Added |
 Rainbow Childrens Medicare | 3.30%Added | 3.78%Added | 3.77% | 3.75%Added | 3.83%Added | 4.23%Added | 4.23% | 4.52%Added | 4.42% | 4.90%Added | 4.47% | 4.30% |
 Cipla | 3.92%Cut | 3.96% | 4.14%Added | 4.69%Added | 4.55% | 5.10%Added | 5.07%Added | 5.18% | 4.77%Cut | 4.53% | 4.27% | 4.22% |
 Torrent Pharmaceuticals | 4.52% | 3.00%Cut | 1.12%Cut | 1.22% | 1.07%Cut | 1.10% | 1.01% | 1.02% | 1.02% | Sold out | 0.12%Bought again | 3.76%Added |
 Max Healthcare Institute | 4.71%Added | 5.65%Added | 5.87%Added | 6.24%Added | 6.78% | 5.14%Cut | 5.17%Added | 4.80% | 5.68%Added | 4.07%Cut | 3.80% | 3.71%Added |
 Lupin | 4.90% | 3.57%Cut | 3.04%Cut | 3.03%Cut | 3.08% | 3.18%Cut | 2.94% | 2.76% | 2.81% | 2.64% | 3.26%Added | 3.14% |
 Bayer Cropscience | – | 3.23%Bought | 3.23% | 3.34% | 3.33% | 3.51% | 3.34% | 3.10%Added | 3.20%Added | 3.26%Added | 3.01% | 2.96%Added |
 Syngene International | 1.76% | 2.35%Added | 2.42%Added | 2.46%Added | 2.39%Added | 2.64%Added | 2.94% | 2.65% | 2.73%Added | 2.95%Added | 3.02% | 2.85% |
 Procter & Gamble Health | – | – | – | – | – | 0.70%Bought again | 1.55%Added | 1.80%Added | 1.79% | 2.42%Added | 2.51%Added | 2.75%Added |
 Sai Life Sciences | 2.09%Added | 1.99%Added | 2.77%Added | 2.77%Added | 3.25%Added | 2.58%Cut | 2.63% | 2.73% | 2.53%Cut | 2.89%Added | 2.41%Cut | 2.60% |
Per cent of the fund's net assets at each month end, Oct 2025 to Sep 2026. Under it, the change on the fund's previous month. "After a gap" is a holding after a month with no portfolio on record, so when it was bought is not known; "Not filed" is one gone across such a gap.
Portfolio turnover, per cent of assets a year
- TurnoverPortfolio turnover. How much of the portfolio the fund bought or sold over the last year, as a share of its assets, as the fund house states it.
Highest 88.0% in Apr 2026
Risk ratios
NAV to 23 Oct 2026
Each bar runs from the lowest to the highest figure among the Direct plans of Sectoral / Thematic funds (130 funds) over the same 3 years; the tick is their average and the dot this fund.
How much the NAV moves
Standard deviationStandard deviation. How far the fund's monthly returns spread around their average, stated as a yearly figure: the wider the spread, the more the NAV moves.16.74%
12.76%Lowest17.49%Average of 138 funds31.25%Highest
Downside deviationDownside deviation. Standard deviation counting only the months in which the fund lost money, stated as a yearly figure.9.43%
5.67%Lowest10.73%Average of 138 funds16.26%Highest
Sharpe ratioSharpe ratio. The monthly return above the 91-day Treasury bill yield, divided by its standard deviation and stated for a year: the extra return for each unit of movement in the NAV.0.75
−0.56Lowest0.47Average of 138 funds1.19Highest
Sortino ratioSortino ratio. The monthly return above the 91-day Treasury bill yield, divided by how far it fell below that yield and stated for a year: the extra return for each unit of movement on the way down.1.22
−0.68Lowest0.75Average of 138 funds2.32Highest
From the Direct Growth plan's NAV, since an IDCW plan's NAV falls by each payout.
Against BSE Healthcare TRI
BetaBeta. How much the fund's monthly return moved for each 1% move in its benchmark: 1 moves with it, below 1 moves less.1.00
0.63Lowest0.93Average1.21Highest
R-squaredR-squared. The share of the fund's monthly movement that its benchmark's movement explains, from 0 to 100.96.7
42.9Lowest87.3Average98.2Highest
CorrelationCorrelation. How closely the fund's monthly returns moved in step with its benchmark's, from minus 1 (always opposite) to 1 (always together).0.98
0.66Lowest0.93Average0.99Highest
Upside captureUpside capture. The fund's return in the months its benchmark rose, as a percentage of the benchmark's return in those months.95.3%
65.5%Lowest99.0%Average134.6%Highest
Downside captureDownside capture. The fund's return in the months its benchmark fell, as a percentage of the benchmark's fall in those months.100.9%
45.6%Lowest87.9%Average118.1%Highest
Information ratioInformation ratio. The fund's return above its benchmark, divided by how much that difference varied, as stated by the fund house.To 30 Sep 2026−0.56
Largest falls
| Largest over | FallLargest fall. The biggest drop in NAV from a high to the low that followed, before the NAV went back above that high. | High on | Low on | Back at the highBack at the high. The first day the NAV closed at or above the high it had fallen from. |
|---|---|---|---|---|
| 1 year | −10.97% | 11 Aug 2026 | 23 Oct 2026 | Not yet |
| 3 and 5 years | −16.81% | 2 Jan 2025 | 28 Feb 2025 | 11 May 2026 |
| 10 years | −18.48% | 19 Feb 2020 | 23 Mar 2020 | 8 Apr 2020 |
| Since Dec 2015 | −19.84% | 1 Feb 2016 | 21 Aug 2017 | 31 Aug 2018 |
Risk level by month
| Months | FundRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month. | BenchmarkBenchmark's risk level. The riskometer level of the fund's benchmark index for the same month, on the same six-step scale as the fund's own. |
|---|---|---|
| Oct 2021 to Aug 202659 months | Very High | Very HighBSE Healthcare TRI |
The riskometer at each month end, the fund's and its benchmark's. A month with none on record is left out.
Tata India Pharma & Healthcare Fund managers
Managers now
| Manager | Return in the manager's time. The change in the plan's NAV from the day the manager took the fund over to the latest NAV; past a year, the yearly rate that would compound to the same change. | Benchmark over the same days. The change in the fund's benchmark index over the same days as the manager's return, worked out the same way, with the dividends of the index's companies added back. | Difference from the benchmark. The fund's return in the manager's time less its benchmark's over the same days, in percentage points. | Portfolio changed after the handover. How much of the portfolio was different three months after the manager took over: half the sum of every holding's change in weight, with each side's holdings scaled to add up to 100 so a move into cash does not count. | Portfolio changed before the handover. The same measure over the three months before the manager took over, since portfolios change anyway. | Assets the manager runs. The latest monthly size of every fund the manager runs now, added up; a fund run with others counts in full for each of its managers, and the line under it counts only the funds they run alone. | ||
|---|---|---|---|---|---|---|---|---|
| Rajat SrivastavaPrimary | Sep 2024 | +1.08%a year | – | – | 10.5% | 4.9% | 1 | ₹1,511 Cr₹1,511 Cr alone |
Returns are the direct plan's growth NAV, from the day each took over to the latest NAV, beside the benchmark over the same days.
Portfolio overlap
Funds holding the most of the same securities, by weight.
Closest funds in the category
| Portfolio overlap. The share of the two funds' portfolios that is the same: for every holding they share, the smaller of its two weights, added up. | Shared holdings. The number of securities both funds hold, cash and futures left out. | |
|---|---|---|
| ITI Pharma and Healthcare FundITI Mutual Fund | 53.71% | 21 |
| Nippon India Pharma FundNippon India Mutual Fund | 52.18% | 22 |
| Aditya Birla Sun Life Pharma and Healthcare FundAditya Birla Sun Life Mutual Fund | 49.93% | 25 |
| SBI Healthcare Opportunities FundSBI Mutual Fund | 48.89% | 19 |
| Mirae Asset Healthcare FundMirae Asset Mutual Fund | 48.73% | 19 |
| UTI Healthcare FundUTI Mutual Fund | 48.69% | 22 |
| HDFC Pharma and Healthcare FundHDFC Mutual Fund | 48.24% | 17 |
| Bandhan Healthcare FundBandhan Mutual Fund | 47.21% | 17 |
| Kotak Healthcare FundKotak Mahindra Mutual Fund | 43.97% | 18 |
| PGIM India Healthcare FundPGIM India Mutual Fund | 43.96% | 19 |
Portfolios for Sep 2026. Overlap is per cent of the portfolio the two funds hold in common.
Tata India Pharma & Healthcare Fund dividend history
IDCW (income distribution cum capital withdrawal), once called a dividend: rupees per unit, paid to holders on the record date and taken out of the NAV.
Every payout
| IDCW payout. Rupees paid out per unit to holders on the record date; the money comes out of the fund, so the plan's NAV falls by the same amount. | IDCW yield. A payout as a share of the plan's NAV on the record date, before the NAV fell by the amount paid. | NAV before | NAV after | |
|---|---|---|---|---|
| 7 May 2026 | ₹1.20 | 3.26% | ₹36.7620 | ₹35.7170 |
The one payout since 7 May 2026.
Changes to the fund
Newest first.
2026
- 1 AprExpenseExpense ratio stated under the new rules: a base ratio, with brokerage, levies and GST on top
2025
- 30 SepBenchmarkBenchmark: Nifty Pharma TRI to BSE Healthcare TRI
Fund details
Objective
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.
Asset allocation
- Equity & equity related instruments of companies in the Pharma & Healthcare Sectors^ 80% - 100%, Other Equity/Equity related instruments 0% - 20%, Money Market Instruments, other liquid instruments**, gold and/or silver instruments/ETF, InvITs as permitted by SEBI 0% - 20%. The scheme may invest in another scheme under the same asset management company or any other mutual fund without charging any fees, provided that aggregate inter-scheme investment made by all schemes under the same management or in schemes under the management of any other asset management company shall not exceed 5% of the net asset value of the mutual fund. Such investments shall be made in the schemes which are permitted by SEBI from time to time.
** Other liquid instruments include cash, bank deposits with Scheduled Commercial Banks, Government Securities, Treasury bills, Repo on Government securities and any other instruments as specified by the SEBI. Units of Equity Mutual funds will be considered under allocation for Equity and Equity related instruments
Type of scheme
An open ended equity scheme investing in Pharma and Healthcare Services Sector.
- Stated category
- Sectoral Fund
- BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back.
- BSE Healthcare TRI
- Risk level at launchRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month.
- Very High
- New fund offer
- 4 Dec 2015 to 8 Dec 2015
- Units first allotted
- 28 Dec 2015
- Open for sale again
- 29 Dec 2015
- Price at the offer
- ₹10 a unit
- Minimum at the offer
- ₹5,000
Plans and codes
| Plan | AMFI code | ISIN | MUTF_IN | First NAV |
|---|---|---|---|---|
| Direct Growth | 135810 | INF277K019A3 | TATA_INDI_PHAR_WGSTAL | 29 Dec 2015 |
| Regular Growth | 135812 | INF277K016A9 | TATA_INDI_PHAR_PSD6HV | 29 Dec 2015 |
| Direct IDCW | 135807 | INF277K010B0 | TATA_INDI_PHAR_3FDOKO | 29 Dec 2015 |
| Regular IDCW | 135809 | INF277K017A7 | TATA_INDI_PHAR_125D75C | 29 Dec 2015 |
This fund
- Scheme information document (opens in a new tab)The fund's objective, terms, costs and risks in full
Factsheet
- Factsheet September 2026 (opens in a new tab)Tata Mutual Fund, Sep 2026
Statement of additional information
- SAI Tata Mutual Fund (opens in a new tab)Tata Mutual Fund, Oct 2026
Annual report
- Annual Report Annexures for F.Y. 2025-2026 (opens in a new tab)Tata Mutual Fund, Mar 2026
- Annual Report for Debt and Cash Schemes (opens in a new tab)Tata Mutual Fund, Mar 2026
- Annual Report for Equity Schemes (opens in a new tab)Tata Mutual Fund, Mar 2026
- Abridged Annual Report for Debt Schemes (opens in a new tab)Tata Mutual Fund, Mar 2026
Riskometer disclosure
- Risk Parameters in respect of Mid Cap and Small Cap equity schemes for FY-2026-27 (opens in a new tab)Tata Mutual Fund, Sep 2026
Portfolio overlap disclosure
- Portfolio Overlap Report as on September 2026 (opens in a new tab)Tata Mutual Fund, Sep 2026